

Rec'd PCT/PTO 21 SEP 2004

#6

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Susan L. Buis
Type or print name of person signing certification

Susan L. Buis 9-21-04
Signature Date


PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ryan Thomas Backer, et al.)
Serial No.: 10/500,476)
International)
Filing Date: January 21, 2003)
For: MELANOCORTIN RECEPTOR AGONISTS)
Docket No.: X-15476)

COMMUNICATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

This application pertains to small molecule and thus doesn't require to disclose nucleotide and/or amino acid sequence.

Respectfully submitted,

Soonhee Jang
Attorney for Applicants
Registration No. 44,802
Phone: 317-651-3571

Eli Lilly and Company
Patent Division/SJ
P.O. Box 6288
Indianapolis, Indiana 46206-6288

BEST AVAILABLE COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address COMMISSIONER FOR PATENTS
PO Box 1470
Alexandria, Virginia 22313-1470
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/500,476	FIRST NAMED APPLICANT Ryan Thomas Backer	ATTY DOCKET NO. X-15476
INTERNATIONAL APPLICATION NO. PCT/US03/00033		
LA. FILING DATE 01/21/2003	PRIORITY DATE	

25885
ELI LILLY AND COMPANY
PATENT DIVISION
P.O. BOX 6288
INDIANAPOLIS, IN 46206-8288

RECEIVED

SEP 14 2004

ELI LILLY & COMPANY, PATENT DEPT.

CONFIRMATION NO. 9111
371 FORMALITIES LETTER

OC000000013730476

Date Mailed: 09/08/2004

Due 11-8-2004

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c) and PCT Rule 5.2(a).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e) and PCT Rule 13ter.1(a)(ii).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patent Software, call (703) 308-2600
 - For Patent Software Program Help, call (703) 308-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 305-3631

BEST AVAILABLE COPY

Fax

Rec'd PCT/PTO 21 SEP 2004
Lilly

Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46205
U.S.A.

LRL LAW - PATENT DEPARTMENT

To: *Barbara A. Campbell*

Company: *USPTO*
Fax: *703-746-6705*
Phone: *703-305-3631*
Date: *September 21, 2004*

From: *Soonhee Jang*
Fax: *317-276-3861*
Phone: *317-651-3571*
Total Pages: *3*

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect), and return the original message to us at the above address via U.S. Postal Service.